1. Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice
- Author
-
Asuka Matsuzaki Tada, Hamizah Shahirah Hamezah, Aslina Pahrudin Arrozi, Zulzikry Hafiz Abu Bakar, Daijiro Yanagisawa, and Ikuo Tooyama
- Subjects
Angiotensin-Converting Enzyme Inhibitors ,Mice, Transgenic ,Amyloid beta-Protein Precursor ,Mice ,Alzheimer Disease ,Presenilin-1 ,Animals ,APP/PS1 mice ,Cognitive Dysfunction ,Inflammation ,Amyloid beta-Peptides ,Receptors, Angiotensin ,Met-Lys-Pro ,Tumor Necrosis Factor-alpha ,Angiotensin II ,General Neuroscience ,Caseins ,NADPH Oxidases ,General Medicine ,MKP ,peptide ,Mice, Inbred C57BL ,Disease Models, Animal ,Psychiatry and Mental health ,Clinical Psychology ,Pharmaceutical Preparations ,Geriatrics and Gerontology ,Oligopeptides ,Alzheimer’s disease ,dementia - Abstract
Background:Tripeptide Met-Lys-Pro (MKP), a component of casein hydrolysates, has effective angiotensin-converting enzyme (ACE) inhibitory activity. Brain angiotensin II enzyme activates the NADPH oxidase complex via angiotensin II receptor type 1 (AT1) and enhances oxidative stress injury. ACE inhibitors improved cognitive function in Alzheimer's disease (AD) mouse models and previous clinical trials. Thus, although undetermined, MKP may be effective against pathological amyloid-β (Aβ) accumulation-induced cognitive impairment., Objective:The current study aimed to investigate the potential of MKP as a pharmaceutical against AD by examining MKP's effect on cognitive function and molecular changes in the brain using double transgenic (APP/PS1) mice., Methods:Experimental procedures were conducted in APP/PS1 mice (n = 38) with a C57BL/6 background. A novel object recognition test was used to evaluate recognition memory. ELISA was used to measure insoluble Aβ40, Aβ42, and TNF-α levels in brain tissue. Immunohistochemical analysis allowed the assessment of glial cell activation in MKP-treated APP/PS1 mice., Results:The novel object recognition test revealed that MKP-treated APP/PS1 mice showed significant improvement in recognition memory. ELISA of brain tissue showed that MKP significantly reduced insoluble Aβ40, Aβ42, and TNF-α levels. Immunohistochemical analysis indicated the suppression of the marker for microglia and reactive astrocytes in MKP-treated APP/PS1 mice., Conclusion:Based on these results, we consider that MKP could ameliorate pathological Aβ accumulation-induced cognitive impairment in APP/PS1 mice. Furthermore, our findings suggest that MKP potentially contributes to preventing cognitive decline in AD.
- Published
- 2022